NICE publishes guidance for NHS England & Wales use of ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia

Technology appraisal guidance [TA344] Published today June 2015
You can access full guidance details on the NICE website here:

Ofatumumab (Arzerra) given with a drug called chlorambucil is recommended as a possible treatment for people with untreated chronic lymphocytic leukaemia if treatments containing fludarabine or bendamustine are not suitable.

What does this mean for me?

If you have chronic lymphocytic leukaemia, and your doctor thinks that ofatumumab with chlorambucil is the right treatment, you should be able to have the treatment on the NHS.

Ofatumumab (with chlorambucil) should be available on the NHS within 3 months of the guidance being issued.

If you are not eligible for treatment as described above, you should be able to continue taking ofatumumab (with chlorambucil) until you and your doctor decide it is the right time to stop.


Last edited by